FDA Expands Pediatric Indication for Rinvoq

FRIDAY, June 21, 2024-- The U.S. Food and Drug Administration has expanded indications for Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic...